Dr. Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer at Genmab A/S is responsible for the overall research organization and strategic drug development functions. Specialists with deep drug development experience in oncology are critical to Genmab’s development efforts – and are among the most difficult to identify, entice, and attract. Dr. Ahmadi works with The Chase Group on his key executive searches because of the firm’s ability to match the vision and needs of Genmab with the motivations, strengths, and goals of the best candidates.
Dr. Tahamtan Ahmadi has made it his life’s work to help people living with cancer by developing transformative antibody therapies.
Not only does it require a tremendous amount of personal drive, tenacity, and acumen, it also requires the right teams. Genmab is pioneering the next generation of antibody platforms to create cancer therapeutics with the potential to improve patients’ lives and as Executive Vice President and Chief Medical Officer, it is Ahmadi’s role to secure the right people to lead those teams. He needs people who share the same passion for research, innovation, and development, but more importantly, he needs people who also fit the team culture.
Ahmadi works with The Chase Group to help find these rare individuals and together, they recently completed the search to find a new Vice President, Multi Compound Medical Head, Solid Tumors.
“As a company, we have worked with The Chase Group for years, but this one was different for me because of my high level of personal involvement,” Ahmadi said. “This search was not easy or straightforward because the role did
not exist when we began, but The Chase Group helped us define it, design it, and map the future dynamics of our team. It was a tough assignment and Chase really stepped up to the challenge.”
Dr. Teng Jin Ong was recruited by The Chase Group to become the newest member of Ahmadi’s clinical development team. He brings both surgical oncology expertise, as well as biopharmaceutical research, clinical development and medical affairs capabilities.
“The Chase Group not only found Dr. Ong but was also able to communicate our vision and help him understand the future possibilities,” Ahmadi said. “Chase made sure this could work for all of us and we were very pleased with the process and the outcome.”
A Unique Candidate for a Unique Opportunity and Company
Ong started his career as a trained surgical oncologist and has deep expertise in cancer drug development, having worked in the biopharmaceutical field for the last 16 years.
“My primary professional goal has always been to advance treatment options for patients in any way I can,” Ong said. “My surgical, clinical development and medical affairs experiences availed me the possibilities to serve in this capacity over the years.”
Ong is enthused to collaborate on the innovation of digital therapeutics and novel opportunities of connected healthcare with real-time data integration techniques that enhance the clinical development framework at Genmab. The flexibility and culture of supporting transformative science at Genmab were major factors in his decision to join the team.
“It was refreshing to work with The Chase Group. They provided detailed feedback as I advanced through the process, so I knew where I stood and what to expect next. They were also constantly checking on perceptions and fit to make sure we were all working toward a mutually beneficial outcome.”
“The products, pipeline, and potential at Genmab are remarkable,” Ong said. “It’s also a privilege to partner with brilliant experts in pursuing breakthrough oncology therapeutics. Together, we can make a difference for patients living with cancer.”
As for the search screening and interview process, Ong said it was well-managed by The Chase Group.
“It was refreshing to work with The Chase Group,” Ong said. “They provided detailed feedback as I advanced through the process, so I knew where I stood and what to expect next. They were also constantly checking on perceptions and fit to make sure we were all working toward a mutually beneficial outcome.”
According to Ahmadi, that was critical, especially in a situation where conversations
- Genmab designs and develops innovative human antibody therapeutics that are making a real difference in the lives of patients living with cancer.
- The Chase Group was retained by Genmab to find a new clinical development medical executive to help the company assess, refine, and accelerate its pipeline, current products, and future plans for human antibody development.
- Dr. Tahamtan Ahmadi, EVP and Chief Medical Officer at Genmab, recently added Dr. Teng Jin Ong to his clinical development team, in a search that he says was managed with precision, skill, and wisdom by The Chase Group.
about the future of the clinical development organization at Genmab were iterating quickly.
“Dr. Ong is a key driver of our future, so we had to get this right and make sure that our vision was aligned with his motivations, goals, and ambitions,” Ahmadi said. “Chase was incredibly insightful helping us understand how to design a unique role for a unique candidate like Dr. Ong.”
Ahmadi also appreciated the professionalism and precision brought to the process by The Chase Group.
“The Chase Group brought us a fantastic group of candidates, kept us informed every step of the way, and did a great job of reconciling the nuances of our needs with the traits of our candidates,” Ahmadi said. “Dr. Ong is an incredible addition to our clinical development team and The Chase Group played a crucial role in making that happen.”